Angiotensin II Type 1 Receptor Blockade Does Not Enhance Apoptotic Cell Death During Ischemia and Reperfusion in Humans In Vivo

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Cardiovascular Pharmacology

• Publication date

  2011-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/FJC.0b013e318218ef21PMID 21423028
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism.

  2010cited by this paper
• Fluvastatin and perioperative events in patients undergoing vascular surgery.

  2009cited by this paper
• Rosuvastatin Increases Extracellular Adenosine Formation in Humans In Vivo: A New Perspective on Cardiovascular Protection

  2009cited by this paper
• Effects of Candesartan Compared With Amlodipine in Hypertensive Patients With High Cardiovascular Risks: Candesartan Antihypertensive Survival Evaluation in Japan Trial

  2008cited by this paper
• Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.

  2007cited by this paper
• Diannexin, a novel annexin V homodimer, provides prolonged protection against hepatic ischemia-reperfusion injury in mice.

  2007cited by this paper
• Diannexin, a Novel Annexin V Homodimer, Protects Rat Liver Transplants Against Cold Ischemia‐Reperfusion Injury

  2007cited by this paper
• Chronic Angiotensin II Receptor Blockade Induces Cardioprotection During Ischemia by Increased PKC-ϵ Expression in the Mouse Heart

  2007cited by this paper
• Postconditioning Protects Against Endothelial Ischemia-Reperfusion Injury in the Human Forearm

  2006cited by this paper
• Caffeine prevents protection in two human models of ischemic preconditioning.

  2006cited by this paper
• Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats

  2005cited by this paper
• Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists.

  2005cited by this paper
• Oral therapy with dipyridamole limits ischemia‐reperfusion injury in humans

  2005cited by this paper
• Annexin A5 Scintigraphy of Forearm as a Novel In Vivo Model of Skeletal Muscle Preconditioning in Humans

  2005cited by this paper
• Angiotensin II Type 2 Receptor–Mediated Vasodilation in Human Coronary Microarteries

  2004cited by this paper
• Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.

  2004cited by this paper
• Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

  2004cited by this paper
• Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

  2003cited by this paper
• Fas pathway is a critical mediator of cardiac myocyte death and MI during ischemia-reperfusion in vivo.

  2003cited by this paper
• Upregulation of Angiotensin II Type 2 Receptor and Limitation of Myocardial Stunning by Angiotensin II Type 1 Receptor Blockers during Reperfused Myocardial Infarction in the Rat

  2003cited by this paper
• Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.

  2002cited by this paper
• Mechanism of the cardioprotective effect of inhibition of the renin-angiotensin system on ischemia/reperfusion-induced myocardial injury.

  2001influential reference
• An angiotensin II type 1 receptor blocker, candesartan, increases myocardial apoptosis in rats with acute ischemia-reperfusion.

  2001cited by this paper
• Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice.

  2001cited by this paper
• International union of pharmacology. XXIII. The angiotensin II receptors.

  2000cited by this paper
• Cardiac functional improvement by a human Bcl‐2 transgene in a mouse model of ischemia/reperfusion injury

  2000cited by this paper
• Visualisation of cell death in vivo in patients with acute myocardial infarction.

  2000cited by this paper
• Effects of losartan on haemodynamic parameters and angiotensin receptor mRNA levels in rat heart after myocardial infarction

  2000cited by this paper
• Annexin V for Flow Cytometric Detection of Phosphatidylserine Expression on B Cells Undergoing Apoptosis

  2000cited by this paper
• Annexin V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death.

  1999cited by this paper
• Angiotensin II type 1 receptor blockade with candesartan protects the porcine myocardium from reperfusion-induced injury.

  1998cited by this paper
• Ischemic preconditioning in pigs: a graded phenomenon: its relation to adenosine and bradykinin.

  1998cited by this paper
• Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group.

  1998cited by this paper
• Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism.

  1997cited by this paper
• Angiotensin II Receptor Antagonist EXP 3174 Reduces Infarct Size Comparable with Enalaprilat and Augments Preconditioning in the Pig Heart

  1997cited by this paper
• Selective blockade of AT1 angiotensin II receptors abolishes ischemic preconditioning in isolated rabbit hearts.

  1997cited by this paper
• Ischaemic preconditioning reduces troponin T release in patients undergoing coronary artery bypass surgery.

  1997cited by this paper
• Selective Blockade of AT1Angiotensin II Receptors Abolishes Ischemic Preconditioning in Isolated Rabbit Hearts

  1997cited by this paper
• Simultaneous high-performance liquid chromatographic determination of caffeine and theophylline for routine drug monitoring in human plasma.

  1996cited by this paper
• Angiotensin II type 2 receptor mediates programmed cell death.

  1996cited by this paper
• Opposite effects of angiotensin AT1 and AT2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts.

  1996cited by this paper
• Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activation.

  1996cited by this paper
• The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer.

  1995cited by this paper
• Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction.

  1995cited by this paper
• Role of bradykinin in protection of ischemic preconditioning in rabbit hearts.

  1995cited by this paper
• Angiotensin-Converting Enzyme Inhibition in Infarct-Induced Heart Failure in Rats: Bradykinin Versus Angiotensin II

  1994cited by this paper
• Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs

  1993cited by this paper
• Preconditioning the human myocardium.

  1993cited by this paper

• Detecting retinal cell stress and apoptosis with DARC: Progression from lab to clinic.

  2021cites this paper
• Annexin V Imaging Detects Diabetes-Accelerated Apoptosis and Monitors the Efficacy of Benfotiamine Treatment in Ischemic Limbs of Mice

  2014cites this paper
• In vivo imaging of retinal ganglion cell apoptosis.

  2013cites this paper
• Assessment of ischaemia and reperfusion injury

  2013cites this paper